Cantor Starts CRISPR Therapeutics (CRSP) at Overweight, 'A Year of Catalysts Could Bring Money Back into This Gene Editing Play'

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Overweight rating and a price target of $72.00.

The analyst comments "We’re initiating coverage on CRISPR Therapeutics (“CRISPR Tx”) with an Overweight rating and a 12- month PT of $72. CRISPR Tx is a leading gene editing company, and the story stands out to us as an interesting gene editing play for 2023. The company has a very good chance of commercializing the first-ever CRISPR gene therapy later this year (a functional cure for sickle cell disease and beta-thalaseemia; we assume a 90% probability of success), and we like the risk/ reward setup for what should be a very busy and transformational year for the company."

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $43.47 yesterday.

You May Also Be Interested In

• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
• Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
• Jack In The Box (JACK) PT Raised to $16 at Mizuho